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Background: The aim of this study is to explore the efficacy of Guizhifulingwan (GFW) in the treatment of climacteric
syndrome in women.
Methods/design: This is a single-center, randomized, placebo-controlled, parallel-group design pilot trial. Fifty
participants with climacteric syndrome will be randomly allocated to the GFW or placebo group in a 1:1 ratio.
The participants will be administered GFW or placebo granules three times a day for 4 weeks and will be followed up
for a further 4 weeks. The primary outcome is the mean change in menopause rating scale score at 5 weeks after
randomization. Secondary outcomes include the World Health Organization quality of life-BREF scores, degrees of
upward movement of qi and lower abdominal resistance and tenderness, blood stasis pattern questionnaire scores, and
results of blood tests including assays for lipid profile, high sensitivity C-reactive protein, follicle-stimulating hormone, and
estradiol. The feasibility outcomes include recruitment and completion rates and adherence to medication.
Discussion: The results of this study will provide basic data for the design of a large-scale clinical trial for evaluating the
efficacy of GFW in the treatment of climacteric syndrome in women.
Trial registration: Clinical Research Information Service (CRIS), Republic of Korea, KCT0002040. Registered on 5
September 2016.
Keywords: Guizhifulingwan, Keishibukuryogan, Climacteric syndrome, Menopause, Randomized controlled trialBackground
Although menopause is a natural phenomenon in women,
the accompanying pre- and post-menopausal symptoms
can considerably affect their daily activities and quality of
life (QOL) [1]. Although hormone replacement therapy
(HRT) is known to be effective for menopausal symptoms
[2], it has been reported to increase the incidence of
thrombosis, stroke, and ovarian cancer [3, 4].
Because of concerns regarding the potential adverse
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medicine is among the more commonly used comple-
mentary and alternative medicines, there is little
evidence supporting its efficacy [5, 6]. Guizhifulingwan
(GFW; Keishibukuryogan in Japanese) has been widely
used for centuries in China, Korea, and Japan for
gynecological disorders caused by blood stasis [7–10]. It
also has been considered effective in the management of
climacteric symptoms. The symptoms for which GFW is
indicated—blood stasis pattern (hot flushes with cold
legs, neck ache, and stiffness), solid constitution (not in
a physically weakened state), ruddy face, etc.— are not
necessarily restricted to women in menopausal transi-
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flushes and perspiration [11, 12].
Although recent clinical studies have evaluated the
efficacy of GFW in the treatment of menopause-related
symptoms [13–15], a randomized controlled trial (RCT)
for validating the same has not yet been undertaken.
Although one of the relevant studies demonstrated a
positive outcome in terms of QOL in menopausal
women upon treatment with GFW, the study neither
included a control group nor described the criteria for
blood stasis pattern during participant selection [13]. On
the other hand, while a previous RCT on hot flushes in
menopausal women did not yield a positive outcome in
this regard, it described the importance of symptom
patterns of each participant in the inclusion criteria [16].
We designed this study to better reflect the characteris-
tics of traditional medicine by considering the traditional
symptom pattern of GFW in the participant inclusion
criteria and assessment methods.
Methods/design
Objective
The aim of this study is to explore the efficacy of GFW
in the treatment of climacteric syndrome in women.
Design
This study will be a randomized, double-blind,
controlled, parallel-group pilot trial. Participants will be
randomly assigned to the GFW or placebo group in a
ratio of 1:1. The study period will be about
8 weeks—4 weeks each of medication and follow-up.
The design is summarized in Figs. 1 and 2. The study
protocol (version 1.1, 25 July 2016) follows the Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) guidelines (see Additional file 1).Fig. 1 Study flow chartRecruitment
Participants will be recruited through advertisements in
local newspapers, the subway, and our hospital.
Participants
Inclusion criteria
Inclusion criteria for the study will be as follows: (1) age,
45–60 years; (2) menopausal women (including those
with natural or induced menopause) with pre- and post-
menopausal climacteric symptoms; (3) menopause rating
scale (MRS) [17, 18] score ≥9; (4) moderate to high
physical strength; (5) moderate to high degree of upward
movement of qi; (6) moderate to high degree of lower
abdominal resistance and tenderness; and (7) willingness
to provide written informed consent.
Natural menopause is considered to have occurred
after 12 consecutive months of amenorrhea with no
other obvious pathological or physiological cause. The
term “climacteric” encompasses perimenopause by
extending the duration of symptoms for a variable
period long before and after menopause. The term “peri-
menopause” includes the period immediately prior to
menopause and the first year after menopause [19].
GFW is generally used for those who are not in a
physically weakened state [10]. The degree of physical
strength of inclusion criterion 4 is evaluated by referen-
cing body physique, nutritional status, and the results of
exclusion criteria 6 and 7 together, and is scored on a
3-point scale (1 = low, 2 =moderate, and 3 = high).
Exclusion criteria
Exclusion criteria for the study are as follows: (1) serious
and unstable medical conditions; (2) severe mental
disease; (3) aspartate aminotransferase (AST), alanine
aminotransferase (ALT), alkaline phosphatase (ALP),
Fig. 2 SPIRIT schedule for enrollment, interventions, and assessments
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as high as or higher than the normal upper limit; (4)
blood urea nitrogen (BUN) and creatinine (Cr) levels 1.5
times as high as or higher than the normal upper limit;
(5) thyroid-stimulating hormone level 1.5 times lower
than the normal lower limit; (6) body mass index <18.5;
(7) hemoglobin (Hb) level <11 g/dL; (8) estrogen therapy
within a year prior to the study; (9) herbal medicine
therapy related to climacteric syndrome within 4 weeks
prior to the study; (10) vaginal bleeding without cause
after menopause; (11) lactose intolerance; (12) participa-
tion in other clinical trials; (13) residents of collective
dwelling facilities such as social welfare institutions;
(14) unwillingness to provide written consent; and (15)
participants judged unsuitable for the clinical trial by the
investigator.Randomization and allocation concealment
A statistician will generate random allocation numbers
using a computer program (SAS [Strategic Applications
Software], version 9.4; SAS Institute Inc., Cary, NC,
USA). The generated numbers will be sealed in opaque
envelopes and stored in double-locked cabinets. Partici-
pants who fulfill all of the inclusion criteria will be
assigned to one of two groups by blocked randomization.
Blinding
The participants, investigators, coordinators, pharmacist,
monitoring agent, and statistician will be blinded to the
group allocation data, which will be known only to the
person in charge of random allocation. The statistician
will create a random allocation table indicating assign-
ment to group A or B. The person in charge of random
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information to the pharmaceutical company (as there is
no one at the investigational products manufacturing
company to create a randomization list, our team will
prepare the randomization table). The pharmaceutical
company will make and label investigational products
based on this information. The label will include each
participant’s identification number (R1001 to R1050;
identical to the random allocation numbers) and visit
number (V1 or V2). An opaque emergency envelope
containing allocation information will be prepared and
stored in a safe place in anticipation of unexpected
events [20]. Violation of blinding will be considered only
under circumstances where knowledge of the medication
being administered to a participant is essential for treat-
ment. The validity of blinding will be assessed according
to the new blinding index [21].
Intervention
Participants will be randomly assigned to the GFW or
placebo control group in a ratio of 1:1. They will receive
treatment or evaluation according to the predetermined
schedule. All participants will orally ingest 3 g of
granules three times a day for 4 weeks and present
themselves for follow-up evaluation 4 weeks after the
termination of medication. The drugs for this clinical
trial will be provided to the participants twice in 2-
week intervals at weeks 1 and 3. To confirm their
adherence to the medication regimen, participants will
be requested to return unused drugs as well as spent
wrappers of used drugs.
Both GFW and the placebo are manufactured by
Hanpoong Pharm. Co., Ltd. (Wanju, Republic of Korea)
according to good manufacturing practice standards.
Only those products that pass quality control tests will
be used in this study. While GFW comprises Ramulus
cinnamomi, Poria, Moutan cortex, Persicae semen, and
Radix paeoniae [9] (3 g of GFW granules are prepared
according to the granulation method using 1.33 g of
GFW soft extract, which is prepared by extracting 1.33 g
of each of the five herbs [same ratio] with water in an
extractor, followed by filtration and concentration), the
placebo comprises corn starch, lactose hydrate, citric
acid hydrate, ginseng flavor powder, and caramel color-
ing. Both these drugs are similar in appearance and color
(brown) and will be packaged in an identical shape.
Concomitant treatment
Participants of both groups will be prohibited from
concomitant use of menopause-related hormone ther-
apy (estrogen, estrogen/progestogen, or tibolone), non-
prescription medicines, functional health foods, or Oriental
medicines that can potentially affect the outcome of this
experiment until after the follow-up period of 8 weeks.Participants who have been on medication for chronic
diseases prior to initiation of this study will be allowed to
continue their regimen, and care will be taken not to alter
the dosage or type of drug. Similarly, participants will be
allowed to maintain their pre-trial exercise routines without
altering the intensity or type of exercise. If the dosage or
type of existing medication or intensity or type of exercise
is changed, the participant will be required to report the
same to the person in charge of this study.
Outcome measurements
The time points for the outcome measurements are
presented in detail in Fig. 2.
Primary outcome
The primary outcome is the mean change in MRS
score at week 5. The MRS comprises 11 items
encompassing 3 subscales: psychological, somato-
vegetative, and urogenital domains. Each item is
scored on a 4-point scale, with scores ranging from 0
(no symptoms) to 4 (very severe). Based on the total
score, determined by the sum of the scores of the
subscales, the degree of symptoms can be classified as
follows: “no, little” (0–4), “mild” (5–8), “moderate”
(9–16), and “severe” (>17) [17, 18]. The Korean
version of the MRS will be used in the present study
(http://www.menopause-rating-scale.info).
Secondary outcomes
World Health Organization QOL-BREF (WHOQOL-
BREF) The WHOQOL-BREF comprises 26 questions
including 24 questions regarding 4 sub-sections—physical
and psychological health, social relationship, and environ-
ment—and 2 questions regarding overall QOL. Each item
is scored on a 5-point scale as follows: 1, strongly disagree;
2, disagree; 3, neutral; 4, agree; and 5, strongly agree. The
Korean version of the WHOQOL-BREF will be used in
the present study [22–24].
Degree of upward movement of qi The degree of
upward movement of qi is evaluated by scoring symp-
toms corresponding to each of five body parts on a
5-point scale (1, no symptoms; 2, mild; 3, moderate;
4, severe; and 5, extreme). The sum of these scores is
divided by 5 to obtain the final value for analysis. If
the final value is a decimal, it is rounded off to one
decimal place. The five body parts and their corre-
sponding symptoms are as follows: head (headache,
dizziness, and heavy-headedness); face (ruddy face and
hot flushes); shoulders (neck and shoulder stiffness);
chest (flushing sensation and palpitation); and lower
limbs (cold legs and feet). These symptoms have been
identified based on previous reports [11, 25, 26], and
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team involved in this study.
Degree of lower abdominal resistance and tenderness
Abdominal examination will be performed according to
the following protocol. The practitioner’s hands should
be sufficiently warm before beginning the examination.
The room itself should be warm enough that the partici-
pant does not shiver or become tense. The participant
lies supine, comfortably, with both legs extended. When
necessary, the exam can be conducted with both knees
bent. The practitioner stands on the right (or left) side
of the participant and first observes the entire abdomen
and then palpates the lower abdomen while trying not to
apply more pressure than necessary [25, 27]. The
abdominal exam is performed from top to bottom and
left to right. The abdominal symptoms of GFW include
a resistance that feels like a palpable mass-like object in
the lower abdomen. Tenderness is not severe [25, 26].
The degree of lower abdominal resistance and tender-
ness is scored on a 5-point scale (1, none; 2, mild; 3,
moderate; 4, severe; and 5, extreme).
Questionnaire for blood stasis pattern The question-
naire for blood stasis pattern comprises 14 items: sprain;
contusion; old BiJeung (BiJeung shows symptoms similar
to those of arthralgia and paresthesia syndrome [28]);
stabbing pain; lower abdominal pain; hypochondriac
pain; night pain; feeling of abdominal mass; easy
congealing of blood; darkish complexion (discoloration
of the face); purple and dull pallor of the mouth, lips,
and tongue; bluish purple discoloration of the lower
eyelid; darkish stools; and number of surgeries. Each
item is scored on a 7-point scale [29].
Blood tests Blood tests including those for internal lipid
(low-density lipoprotein, high-density lipoprotein, total
cholesterol, and triglycerides), high sensitivity C-reactive
protein (for prediction of risk of cardiovascular diseases
[30]), and hormone (follicle-stimulating hormone and
estradiol, for understanding the climacteric condition)
levels will be conducted.
Feasibility outcomes
Recruitment rate The recruitment rate will be calculated
as the percentage of participants selected from among
those who undergo screening and the percentage of par-
ticipants selected against the total number of participants.
Completion rate The completion rate will be calculated
as the percentage of participants who complete the study
without interruption until the endpoint against the total
number of participants.Medication adherence Medication adherence will be
calculated as the percentage of doses ingested by the
participants against the total dose.
Safety and adverse event outcomes
Adverse events (AEs) indicate undesirable and uninten-
tional signs, symptoms, or diseases that develop after
intervention during the period of a clinical trial. They do
not necessarily have a causal relationship with the
relevant intervention. Investigators will check partici-
pants’ vital signs and examine for manifestation of AEs,
including digestive symptoms, skin conditions, and
jaundice, at every visit. Investigators will also conduct
physical examination and laboratory tests, including
evaluation of AST, ALT, ALP, γ-GTP, BUN, Cr, Hb, and
hematocrit levels and red and white blood cell, differen-
tial, and platelet counts, at the screening as well as at
the fourth visit (week 9). In case of AEs, the correlation
between AEs and intervention will be classified into one
of the following six categories: (1) definitely related, (2)
appears to be related, (3) possibly related, (4) appears to
be unrelated, (5) definitely not related, or (6) unclear.
Sample size
The null hypothesis (H0) of this study is that there will
be no difference in the mean change in MRS scores
between the GFW and placebo groups after 4 weeks of
medication. The alternative hypothesis (H1) is the
opposite scenario of H0. In the GFW group of a previous
study [13], the mean change in MRS scores from base-
line to day 30 was −7.27; the authors determined the
mean change in MRS scores of the control group to
be −1.45 under the assumption that it would corres-
pond to approximately 20% of the value observed with the
treatment group. With this previous study [13] as a
reference, we assumed that the standard deviation of
change in MRS scores from baseline to week 4 will be 6.73.
With a 5% significance level and 80% power, the sample
size was determined to be 21 participants per group:




¼ 2 1:96 þ 0:84ð Þ
2 6:73ð Þ2
−5:82ð Þ2 20:97≈21
Considering a 15% dropout rate, we determined that
25 participants will be ideally required per group.
Statistical analysis
The analysis set will comprise a full analysis set (FAS)
and a per-protocol set (PPS). The FAS will include
participants who satisfy the intention-to-treat principle
as completely as possible. The PPS will include partici-
pants who are more compliant with the study protocol
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Analysis of covariance will be performed to evaluate the
values of outcomes at weeks 5 and 9 as dependent
variables, the baseline values as covariates, and the
group as a constant. Participants will be divided into
pre- and post-menopausal groups, which will be evalu-
ated by exploratory subgroup analysis according to MRS
scores in order to determine whether the intervention is
equally effective on both subgroups. Intra-group
comparisons will be performed by the paired t test or
Wilcoxon signed-rank test. The analyses will be per-
formed considering an α-value of 5% and a power of
80%. Missing data will be imputed by multiple imput-
ation. For socio-demographic characteristics, continuous
variables will be presented as mean value and standard
deviation, while categorical variables will be presented as
frequency and percentage. Statistical analysis will be
performed using the SAS program (version 9.4; SAS
Institute Inc., Cary, NC, USA).
Data and safety monitoring
The trial data will be saved in an electronic data capture
system (Medidata Rave; Medidata Solutions Inc., New
York, NY, USA). Data quality will be ensured by regular
monitoring. The monitoring agent will confirm whether
the data are consistent with the source documents and
whether the trial is conducted according to the approved
protocol. All AEs observed during the study period will
be recorded and reported.
Discussion
The purpose of this study is to explore the efficacy of
GFW in the treatment of climacteric syndrome in
women with blood stasis pattern. The study will also
serve to monitor the safety of GFW.
Traditional Chinese medicine (TCM) has been
adopted in a modified form in East Asian countries such
as Japan and Korea [32, 33]. The system of pattern iden-
tification—the process of overall analysis of clinical data
to determine the location, cause, and nature of disease
in a patient and diagnosing a pattern/syndrome
[34]—practiced in the three countries varies to a certain
extent. In TCM, a practitioner recognizes the “Zheng”
(clinical diagnosis based on analysis of medical history,
symptoms, and signs) and confirms the treatment
principle. In traditional Japanese medicine (Kampo), a
practitioner chooses the most appropriate formula from
among approximately 150 ready-to-use formulas,
according to the “Sho” (pattern of symptoms) of the
patient [32, 35]. Kampo can be characterized as a simpli-
fied and pragmatic version of Chinese herbal medicine
[36]. In traditional Korean medicine (TKM), disease and
pattern identification are made simultaneously as
described in Dongui Bogam [37], which was compiled inthe 17th century. TKM has been developed to include
various modified methods involving the application of
existing principles, methods, and formulas [38]. The
diagnostic system of TKM includes the determination of
diagnostic criteria based on indications for prescription
of herbal medicines for a certain disease or its etiology
[39–42]. Standardization of diverse pattern identification
systems has been inadequate until now, which has made
it challenging to apply pattern identification to clinical
research on traditional medicine [43–46]. For the find-
ings of clinical studies to be of direct aid in medical
decision-making in traditional clinical practice, pattern
identification systems used in routine practice need to
be accurately reflected in the study design [44, 45]. The
present trial was planned in consideration of the target
symptoms for herbal formulas, with Western medical
methods for participant selection and outcome measure-
ment. This approach is in agreement with a previous pro-
posal for complementation of clinical research methods in
traditional medicine [39].
Although the pattern identification and outcome
measurement methods of this study are not ideal, they
could serve as a reference for planning clinical trials that
reflect the characteristics of traditional medicine. The
results of this study will provide basic data for the design-
ing of a large-scale trial evaluating the efficacy of GFW for
the treatment of climacteric syndrome in women.
Trial status
Recruitment began in mid-October 2016.
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